EANS-News: Epigenomics AG / Epigenomics AG Successfully Completes Capital Increase

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Subtitle: Not for distribution in the United States

Restructuring & Recapitalisations/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Epigenomics
AG (Frankfurt Prime Standard: ECX), the German-American cancer
molecular diagnostics company, today announced the successful
completion of a capital increase by way of a rights issue and a
subsequent private placement. Gross proceeds amount to EUR 4,976,099,
extending, based upon current projections, the cash runway of the
Company at least into Q4 2013.

In line with previous announcements, and supported by the recent
submission of its Premarket Approval (PMA) to the United States Food
& Drug Administration (FDA) for its blood-based Epi proColon® test
for the detection of colorectal cancer in December 2012, Epigenomics
will continue to explore all strategic options for the Company. These
options especially include the possibility of securing additional
financial resources to support the Company's operations up to and
beyond a potential U.S. Food and Drug Administration (FDA) approval
for Epi proColon®.

Dr. Thomas Taapken, Chief Financial Officer and acting Chief
Executive Officer of Epigenomics, commented: "We are pleased about
the outcome of this financing and thank all of our shareholders and
new investors who participated in the capital increase. The
completion of the PMA submission to the FDA by year end 2012 and the
proceeds of this financing bring the Company closer to potential FDA
approval for Epi proColon®, while alleviating our financial
situation."

Transaction outline:

On January 25, 2013, the Executive Board of Epigenomics AG, Berlin,
Germany (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516), with the
approval of the Supervisory Board, has taken the decision to
implement the capital increase from authorized capital, the details
of which were announced on January 7, 2013, for the maximum number of
3,149,430 new ordinary bearer shares, generating gross proceeds of
EUR 4,976,099.

2,811,707 new ordinary bearer shares were taken up by the
shareholders at a subscription price of EUR 1.58 per new share during
the subscription period which started on January 11, 2013 and ended
on January 24, 2013. The remaining 337,723 unsubscribed new shares
were sold at the subscription price of EUR 1.58 per new share in a
private placement to institutional investors. The private placement
was significantly oversubscribed, enabling Epigenomics AG to place
the maximum number of new shares. The capital increase was conducted
by Kempen & Co.

The registration of the implementation of the capital increase with
the commercial register ("Handelsregister") and the admission of the
new shares to the regulated market ("regulierter Markt"), Prime
Standard, of the Frankfurt Stock Exchange are expected on or around
January 29, 2013. Trading in the new shares is expected to begin on
January 30, 2013, and delivery of the new shares to the investors is
expected on January 31, 2013. With the registration of the
implementation of the capital increase the total issued share capital
of Epigenomics increases from EUR 8,818,417.00 to EUR 11,967,847.00.

Epigenomics AG intends to use the net proceeds from the share capital
increase to finance its current operations.

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics Epigenomics (www.epigenomics.com) is a molecular
diagnostics company developing and commercializing a pipeline of
proprietary products for cancer. The Company's products enable
doctors to diagnose cancer earlier and more accurately, leading to
improved outcomes for patients. Epigenomics' lead product, Epi
proColon®, is a blood-based test for the early detection of
colorectal cancer, which is currently marketed in Europe and is in
development for the U.S.A. The Company's technology and products have
been validated through multiple partnerships with leading global
diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations
in Europe and the U.S.A.

Epigenomics legal disclaimer This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English